|
May 10
|
Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71
|
|
May 8
|
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Q1 2024 Abcellera Biologics Inc Earnings Call
|
|
May 8
|
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
|
|
May 7
|
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates
|
|
May 7
|
AbCellera Reports Q1 2024 Business Results
|
|
May 2
|
Insider Stock Buying Reaches US$1.61m On AbCellera Biologics
|
|
May 1
|
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
May 1
|
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
|
|
Apr 30
|
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 8
|
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
|
|
Apr 3
|
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
|
|
Mar 27
|
The 7 Best Penny Stocks to Buy in Q2 2024
|
|
Mar 26
|
Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks
|
|
Mar 19
|
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
|
|
Mar 11
|
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
|
|
Mar 5
|
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
|
|
Feb 1
|
Techne (TECH) Q2 Earnings and Revenues Lag Estimates
|
|
Jan 30
|
Baillie Gifford Adjusts Stake in AbCellera Biologics Inc
|